ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biogen is teaming with the Gainesville, Fla.-based gene therapy firm AGTC to develop drugs for ophthalmic diseases. Biogen will pay AGTC $124 million up front in exchange for worldwide rights to two drug candidates, a gene therapy for X-linked retinoschisis currently in clinical studies and a preclinical therapy for X-linked retinitis pigmentosa. Biogen also gets an option to license earlier-stage candidates for three other diseases.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter